Fatty liver disease (MASLD/MASH): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0
• CD40 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,999 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

  NCT03587831· University of Minnesota· Updated 30 Sept 2026

  “Study has been terminated due to poor recruitment and early evidence of futility”Registry text, quoted unchanged. Source

• Suspended

  NAFLD in Adolescents and Young Adults With PCOS

  NCT02506946· Columbia University· Updated 30 Sept 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Non-alcoholic Steatohepatitis Registry Platform Study

  NCT06123858· AstraZeneca· Updated 29 Jul 2026

  “Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Updated 13 Jul 2026

  “no grant approved”Registry text, quoted unchanged. Source

• Withdrawn

  Assessment of Fatty Liver With Thermo-acoustic Device

  NCT04302051· Medical College of Wisconsin· Updated 10 Jul 2026

  “The sponsor withdrew from the study”Registry text, quoted unchanged. Source

• Terminated

  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

  NCT04365868· Galectin Therapeutics Inc.· Updated 30 Jun 2026

  “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”Registry text, quoted unchanged. Source

• Terminated

  Prevention of NAFLD in Hispanic Children

  NCT05292352· Emory University· Updated 2 Jun 2026

  “Study was terminated due to a lack of funding. Data collection was completed for 12-month outcomes; however, funding limitations prevented follow-up for longer timeframes, and some outcomes were not fully collected.”Registry text, quoted unchanged. Source

• Terminated

  Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

  NCT06939816· Enyo Pharma· Updated 23 Apr 2026

  “Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.”Registry text, quoted unchanged. Source

• Terminated

  A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

  NCT06007651· Eli Lilly and Company· Updated 13 Apr 2026

  “Participants were not dosed in Part B as per the protocol.”Registry text, quoted unchanged. Source

• Withdrawn

  FCI Effectiveness in NAFLD Stratification

  NCT05827432· NHS Grampian· Updated 1 Apr 2026

  “Funding period ended.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Isocaloric Navy-Bean Substitution in Adults With MASLD

  NCT07730853· Icahn School of Medicine at Mount Sinai· Source

• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Regeneron Pharmaceuticals· Source

• A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07701993· GlaxoSmithKline· Source

• A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

  NCT07358546· GlaxoSmithKline· Source

• Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT07854782· Regeneron Pharmaceuticals· Source

• A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07704892· GlaxoSmithKline· Source

• Effect of Ancestry Supplementation in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  NCT07592013· University of Guadalajara· Source

• A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

  NCT06836609· Regeneron Pharmaceuticals· Source

• Accurate Point of Care Liver Disease Diagnostics (Phase 2)

  NCT07518784· University of California, San Diego· Source

• ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Boehringer Ingelheim· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 65
• Metabolomics 103
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 101
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 171
• Genome-Wide Association Study 48

• Intrahepatic Tissue-Resident CD8+ T-Cell Programmes Associate With Fibrosis and Local Immune Remodelling in Autoimmune Hepatitis.

  Liver Int, Nov 2026

• Managing Autofluorescence in Spectral Flow Cytometry for Macrophage Identification in the Liver.

  Eur J Immunol, Jun 2026

• Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro.

  Pharmacology, Sept 2009

See which targets of this disease your abstract mentions, and go to the people working on them.